Metformin
Metformin induces short-term IGF-I reduction among cancer survivors with obesity
Metformin significantly reduces insulin-like growth factor I levels after 3 to 6 months among cancer survivors with obesity, but the effect wanes over time, according to data published in The Journal of Clinical Endocrinology & Metabolism.
Should SGLT2 inhibitors be first-line therapy for type 2 diabetes?
As far as SGLT2 inhibitors for first-line therapy in type 2 diabetes, the question should be, why not? What other drug class, apart from insulin, can be prescribed and it works immediately, without the need for titration? SGLT2 inhibitors are insulin-independent. There is no risk for hypoglycemia. There is no risk for weight gain. They work for everyone, as long as you have a kidney.
High blood glucose at admission, insulin use raise risk for COVID-19 mortality in diabetes
People with diabetes who have elevated blood glucose levels at admission and those who take insulin are at increased risk for COVID-19 mortality, according to data from a systematic review and meta-analysis published in Diabetologia.
Use of metformin, newer drugs on the rise in patients with diabetic kidney disease
Between 2007 and 2016, researchers observed that use of metformin and newer glucose-lowering medications increased significantly for patients with chronic kidney disease and type 2 diabetes.
One-fifth of COVID-19 patients with diabetes die within 28 days of hospitalization
New data from the CORONADO study show that 20% of people with diabetes hospitalized with COVID-19 die within 28 days of admission, whereas half are discharged in that same time span.
Metformin use may reduce risk for AMD
Top in hem/onc: Breast cancer incidence, cancer risk in diabetes
Female breast cancer has superseded lung cancer as the world’s most common cancer diagnosis, according to a recent report. It was the top story in hematology/oncology last week.
Top in endocrinology: Obesity treatment, COVID-19 mortality in metformin users
A once-monthly monoclonal antibody reduced body fat and increased muscle in patients with type 2 diabetes and overweight or obesity, according to a recent study. It was the top story in endocrinology last week.
COVID-19 mortality odds lower for metformin users with diabetes
Prior use of metformin was associated with a threefold decrease in COVID-19 mortality for people with diabetes independent of glucose profile and BMI, according to study data.
Type 2 diabetes, metformin use impact risk for breast cancer subtypes
Women with type 2 diabetes and those who used metformin did not demonstrate an overall increased risk for breast cancer, according to an analysis of the Sister Study published in Annals of Oncology.